Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.88 |
| ▸ | POLB | P06746 | 8/20 | 0.88 |
| ▸ | MEN1 | O00255 | 8/20 | 0.88 |
| ▸ | RAB9A | P51151 | 4/20 | 0.88 |
| ▸ | NPC1 | O15118 | 3/20 | 0.88 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.88 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.88 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.83 |
| ▸ | CTDSP1 | Q9GZU7 | 5/20 | 0.61 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.61 |
| ▸ | GRK2 | P25098 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | APEX1 | P27695 | 3/20 | 0.60 |
| ▸ | PTGES | O14684 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395526 | 1.00 | KMT2A (0.88) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL29494139 | 0.92 | KMT2A (0.75) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL46551 | 0.80 | SLC1A3 (0.73) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL5145176 | 0.80 | SLC1A3 (0.73) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL30115002 | 0.79 | POLB (0.70) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL5145237 | 0.79 | SLC1A3 (1.00) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL5145242 | 0.79 | SLC1A3 (1.00) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL6389833 | 0.78 | MEN1 (0.70) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL6389826 | 0.78 | MEN1 (0.70) | KMT2APOLBMEN1RAB9ANPC1 | |
| SCHEMBL5167537 | 0.78 | MEN1 (0.62) | KMT2APOLBMEN1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165121-A | Fusion protein containing NB237, gene expression silencing tool containing fusion protein and application of fusion protein | 北京因诺惟康医药科技有限公司 | 2024-06-11 | — | — | CN | claimed |
| EP-4735597-A1 | RNA INTERFERENCE MEDIATED THERAPY FOR NEOPLASTIC DISEASES | Università degli Studi del Piemonte Orientale "Amedeo Avogadro" (IT) | 2026-05-06 | — | — | EP | disclosed |
| EP-4696322-A2 | INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY | Nalpropion Pharmaceuticals LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4349369-B1 | INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY | NALPROPION PHARMACEUTICALS LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025003985-A1 | RNA INTERFERENCE MEDIATED THERAPY FOR NEOPLASTIC DISEASES | Università Degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT) | 2025-01-02 | — | — | WO | disclosed |
| CN-118165121-A | Fusion protein containing NB237, gene expression silencing tool containing fusion protein and application of fusion protein | 北京因诺惟康医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118165121-A | Fusion protein containing NB237, gene expression silencing tool containing fusion protein and application of fusion protein | 北京因诺惟康医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118165121-A | Fusion protein containing NB237, gene expression silencing tool containing fusion protein and application of fusion protein | 北京因诺惟康医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-4349369-A2 | INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY | Nalpropion Pharmaceuticals LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024036184-A2 | A HUMAN VH-BASED SCAFFOLD FOR THE PRODUCTION OF SINGLE DOMAIN ANTIBODIES AND THEIR USE | INTERNATIONAL AIDS VACCINE INITIATIVE (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-3884947-B1 | INCREASING DRUG BIOAVAILABILITY IN NALTREXONE THERAPY | NALPROPION PHARMACEUTICALS LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230053121-A1 | HIERARCHICAL, PARALLEL MODELS FOR EXTRACTING IN REAL TIME HIGH-VALUE INFORMATION FROM DATA STREAMS AND SYSTEM AND METHOD FOR CREATION OF SAME | TARGET BRANDS INC (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220233520-A1 | Increasing Drug Bioavailability In Naltrexone Therapy | NALPROPION PHARMACEUTICALS LLC (US) | 2022-07-28 | — | — | US | disclosed |
| US-11366859-B2 | Hierarchical, parallel models for extracting in real time high-value information from data streams and system and method for creation of same | TARGET BRANDS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20220105087-A1 | Increasing Drug Bioavailability In Naltrexone Therapy | NALPROPION PHARMACEUTICALS LLC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220088007-A1 | Increasing Drug Bioavailability In Naltrexone Therapy | NALPROPION PHARMACEUTICALS LLC (US) | 2022-03-24 | — | — | US | disclosed |
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | KMT2A 4410/4885POLB 2945/4885MEN1 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.